Copyright (c) 2009 Yahoo! Inc. All rights reserved.http://finance.yahoo.com/q/h?s=alxnLatest Financial News for Alexion Pharmaceuticals, Inc.en-usMon, 21 Dec 2009 21:49:00 Etc/GMThttp://us.news2.yimg.com/us.yimg.com/p/fi/pr/40197.gifhttp://finance.yahoo.com14417http://us.rd.yahoo.com/finance/external/xbarronsblog/rss/SIG=12nq64t7k/*http%3A//blogs.barrons.com/stockstowatchtoday/2009/12/21/rigel-pharma-gives-up-gains/?mod=yahoobarronsyahoo_finance/2492507106Mon, 21 Dec 2009 21:49:00 Etc/GMThttp://us.rd.yahoo.com/finance/external/mfool/rss/SIG=12s0jkpro/*http%3A//www.fool.com/retirement/general/2009/12/08/how-to-profit-from-the-new-normal.aspx?source=eptyholnk303100&logvisit=y&npu=yyahoo_finance/1107504124Tue, 8 Dec 2009 16:49:35 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091207/20091207005410.html?.v=1CHESHIRE, Conn.----New data presented today demonstrate the severe clinical burden of paroxysmal nocturnal hemoglobinuria and the clinical benefits of Soliris® in 44 patients with no history of prior blood transfusions.yahoo_finance/2388626163Mon, 7 Dec 2009 16:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091207/20091207005413.html?.v=1CHESHIRE, Conn.----Soliris® , a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. , reversed thrombocytopenia in a significant proportion of patients with both paroxysmal nocturnal hemoglobinuria and pre-existing thrombocytopenia, according to an analysis of data from 49 patients enrolled in clinical trials of Soliris in PNH.yahoo_finance/3131572640Mon, 7 Dec 2009 16:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091206/20091206005072.html?.v=1CHESHIRE, Conn.----Alexion Pharmaceuticals, Inc. today announced presentation of data showing that the presence of Type II paroxysmal nocturnal hemoglobinuria cells is correlated with thrombocytopenia, potentially indicating that patients with Type II cells experience ongoing platelet consumption and increased thrombosis risk.yahoo_finance/3542758369Sun, 6 Dec 2009 15:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091206/20091206005073.html?.v=1CHESHIRE, Conn.----Soliris® , a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. , reduced hemolysis and transfusion requirements, and improved measures of fatigue, when added to ongoing immunosuppressive therapy in patients with both paroxysmal nocturnal hemoglobinuria and bone marrow insufficiency , including aplastic anemia .yahoo_finance/91336100Sun, 6 Dec 2009 15:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091205/20091205005013.html?.v=1CHESHIRE, Conn.----Alexion Pharmaceuticals, Inc. today announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris® for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria .yahoo_finance/1571155008Sat, 5 Dec 2009 15:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/zacks/091204/27926.html?.v=1yahoo_finance/2338996976Fri, 4 Dec 2009 13:51:43 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091202/alxn8-k.htmlyahoo_finance/1469049251Wed, 2 Dec 2009 18:01:57 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/ap/091202/us_alexion_pharmaceuticals_facility.html?.v=1Biotechnology company Alexion Pharmaceuticals Inc. said Wednesday an advisory panel in Europe recommended commissioning of the company's Smithfield, R.I. manufacturing facility.yahoo_finance/177435877Wed, 2 Dec 2009 12:53:46 Etc/GMThttp://us.rd.yahoo.com/finance/external/reuters/rss/SIG=118cks9u6/*http%3A//www.reuters.com/legacyArticle?duid=mtfh21513_2009-12-02_12-38-51_bng435596_newsml&rpc=44&type=marketsNewsyahoo_finance/3539376061Wed, 2 Dec 2009 12:38:51 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091202/20091202005428.html?.v=1CHESHIRE, Conn.----Alexion Pharmaceuticals, Inc. today provided updates on the regulatory review and approval, or commissioning, of Alexion’s Rhode Island manufacturing facility in Smithfield, Rhode Island as a second source of supply for Soliris® .yahoo_finance/3321937256Wed, 2 Dec 2009 11:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091201/20091201006457.html?.v=1CHESHIRE, Conn.----Alexion Pharmaceuticals, Inc. today announced that Mr. William R. Keller has been appointed a Director of Alexion, effective immediately. With Mr. Keller’s appointment, there are now eight members of Alexion’s Board of Directors.yahoo_finance/1214082009Tue, 1 Dec 2009 21:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/external/mfool/rss/SIG=12qdq7js9/*http%3A//www.fool.com/investing/mutual-funds/2009/11/16/the-hottest-sector-for-2010.aspx?source=eptyholnk303100&logvisit=y&npu=yyahoo_finance/2896661430Mon, 16 Nov 2009 20:02:11 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091111/20091111005285.html?.v=1CHESHIRE, Conn.----Alexion Pharmaceuticals, Inc. today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at Lazard Capital Markets 6th Annual Healthcare Conference in New York City at 10:00 a.m.yahoo_finance/3521125167Wed, 11 Nov 2009 15:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/q/is?s=alxnyahoo_finance/919955053Wed, 11 Nov 2009 14:04:44 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091110/20091110006728.html?.v=1CHESHIRE, Conn.----Alexion Pharmaceuticals, Inc. today announced that researchers are scheduled to present data relating to Soliris® as a treatment for patients with paroxysmal nocturnal hemoglobinuria during the 51st Annual Meeting of the American Society of Hematology , to be held December 5 – 8, 2009 at the Ernst N.yahoo_finance/3924544914Tue, 10 Nov 2009 23:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091105/alxn10-q.htmlyahoo_finance/3556942960Thu, 5 Nov 2009 22:19:39 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091105/20091105006309.html?.v=1CHESHIRE, Conn.----Alexion Pharmaceuticals, Inc. today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at Credit Suisse’s 2009 Healthcare Conference in Phoenix, Arizona at 8:00 a.m., local time on Thursday, November 12, 2009.yahoo_finance/304938997Thu, 5 Nov 2009 19:47:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/twst/091105/pharma17.html?.v=1yahoo_finance/1794145737Thu, 5 Nov 2009 17:16:00 Etc/GMT